|
|
|||||||||||||
 |
Home > Diagnosis & Monitoring > Osteoporosis
|
Osteoporosis
Overview
|
 |
 |
|
Osteoporosis is characterized by a decrease in bone mass due to a dysequilibrium between bone resorption and bone formation, i.e., osteoclast and osteoblast activity. The highest incidence is in postmenopausal women due to bone mass loss related to the reduction in estrogen production
In the physician's office it is essential to detect patients with osteoporosis early on and to identify patients at risk for osteoporosis and fractures. Specific bone markers such as β-CrossLaps for bone resorption and osteocalcin for bone turnover are becoming increasingly important. Bone markers should therefore be routinely assessed for risk stratification of postmenopausal women. In contrast to bone mineral density determination determination of bone markers allow for a monitoring of therapeutic efficacy as early as 3 months after initiating an anti-resorptive treatment.
 |
|
||
|
||
| © 2009, Roche Diagnostics | See our Legal Statement | |
|
||
|
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin. |
||
